April 16th, 2020 | 07:55 CEST
Johnson & Johnson, Memphasys, Procter & Gamble - for a better life
Good health is a valuable possession. Small and large companies around the globe are engaged in research and development to make people's lives easier or better through modern and innovative products and solutions. The consumer goods and pharmaceutical sectors often offer attractive opportunities for investors to generate a lucrative return. Well-known companies with established brands usually ensure lasting sales. However, promising young companies also use innovations to attract the attention of investors and customers.
time to read: 1 minutes | Author: Mario Hose
ISIN: US4781601046 , AU000000MEM5 , US7427181091
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Innovation helps with the desire for children
Memphasys from Australia deals with the subject of in-vitro fertilization. The target groups are couples who wish to have children but have not yet been able to achieve a successful pregnancy by natural means. The company has developed a product called FELIX, which is used in the field of bio-separation of sperm. With this innovation, the particularly promising sperm cells are separated from the seminal fluid in just a few minutes to increase the chances of a successful pregnancy. Initially, the focus is on artificial insemination of humans, but in the future animals will also be accompanied.
Alison Coutts is Executive Chairman of Memphasys and explains the product and future areas of application in a video - youtu.be/kHA-UhbeZH8. FELIX is expected to be launched in the second half of 2020. The company currently has a market capitalization of around AUD 35 million and a successful market launch offers corresponding potential for the shares.
Group with brands
Johnson & Johnson is a broad-based group from the USA and is a member of the Dow Jones Index. The market value of the company is around USD 390 billion. Johnson & Johnson products are available under various brands worldwide and can be found in virtually every household. The pharmaceutical and consumer goods manufacturer has a highly diversified product universe and can therefore benefit from a variety of revenue streams. Optimal conditions for conservative investors.
Dividend stock with consumer goods
Procter & Gamble is also a member of the Dow Jones Index and has a market capitalization of approximately USD 300 billion. The manufacturer of consumer goods can also offer a wide range of products from around the world on the shelves of drugstores and supermarkets. The company aims to improve the lives of its customers with products in the Care, Hygiene, Healthcare and Household segments. Due to the size of the company and the diversity of its product range, the dividend stock can build on numerous revenue streams and drive development.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
